Harmony Biosciences Holdings Inc (HRMY) Stock Price, Quote & News

Latest News on HRMY

Jun 5, 2025, 8:05 AM EDT - 1 day ago

Harmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA Litigation

Jun 4, 2025, 8:05 AM EDT - 2 days ago

Harmony Biosciences to Participate in Goldman Sachs 46th Annual Global Healthcare Conference

May 6, 2025, 5:05 PM EDT - 4 weeks ago

Harmony Biosciences Holdings, Inc. (HRMY) Q1 2025 Earnings Call Transcript

May 6, 2025, 7:30 AM EDT - 4 weeks ago

Harmony Biosciences Reports Strong Q1 2025 Financial Results, Highlights Advancement of Its Pipeline and Upcoming Catalysts, and Reaffirms 2025 Revenue Guidance

Apr 29, 2025, 8:05 AM EDT - 5 weeks ago

Harmony Biosciences to Report First Quarter 2025 Financial Results on May 6, 2025

Apr 8, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Shareholders to Connect

Apr 8, 2025, 8:05 AM EDT - 2 months ago

Harmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome

Apr 7, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Shareholders to Reach Out

Apr 6, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Harmony Biosciences Holdings, Inc. (HRMY) and Encourages Shareholders to Learn More About the Investigation

Apr 4, 2025, 10:00 AM EDT - 2 months ago

Harmony Biosciences Holdings, Inc. (HRMY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Apr 3, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Harmony Biosciences Holdings, Inc. (HRMY) and Encourages Investors to Learn More About the Investigation

Apr 3, 2025, 8:05 AM EDT - 2 months ago

Harmony Biosciences Appoints Biotech Leader Ron Philip to Its Board of Directors

Apr 2, 2025, 10:00 AM EDT - 2 months ago

Harmony Biosciences Holdings, Inc. (HRMY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Apr 1, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Investors to Connect

Mar 31, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Harmony Biosciences Holdings, Inc. (HRMY) Stockholders to Inquire about Securities Investigation

Mar 28, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Stockholders to Connect

Mar 27, 2025, 10:00 AM EDT - 2 months ago

Harmony Biosciences Holdings, Inc. (HRMY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Mar 26, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Harmony Biosciences Holdings, Inc. (HRMY) and Encourages Stockholders to Learn More About the Investigation

Mar 26, 2025, 8:05 AM EDT - 2 months ago

Harmony Biosciences to Participate in 24th Annual Needham Virtual Healthcare Conference

Mar 25, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Harmony Biosciences Holdings, Inc. (HRMY) Investors to Inquire about Securities Investigation

Mar 24, 2025, 2:00 PM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Investors to Reach Out

Mar 24, 2025, 12:09 PM EDT - 2 months ago

Harmony Biosciences: A Compelling Risk-Reward Opportunity

Mar 24, 2025, 8:05 AM EDT - 2 months ago

Harmony Biosciences Names Adam Zaeske as Chief Commercial Officer to Lead the Next Phase of Commercial Growth as Its Portfolio Expands

Mar 21, 2025, 7:45 PM EDT - 2 months ago

HRMY Investors Have Opportunity to Join Harmony Biosciences Holdings, Inc. Fraud Investigation with the Schall Law Firm

Mar 4, 2025, 8:05 AM EST - 3 months ago

Harmony Biosciences to Participate in Upcoming Investor Conferences

Feb 25, 2025, 3:05 PM EST - 3 months ago

Harmony Biosciences Holdings, Inc. (HRMY) Q4 2024 Earnings Call Transcript

Feb 25, 2025, 7:30 AM EST - 3 months ago

Harmony Biosciences Reports Strong 2024 Financial Results and Reiterates 2025 Net Revenue Guidance; Highlights 2025 Catalysts in Sleep/Wake and Fragile X Syndrome Development Programs

Feb 19, 2025, 2:24 PM EST - 3 months ago

Harmony Biosciences Stock Falls On FDA Setback For Pitolisant In Sleeping Disorder

Feb 19, 2025, 8:05 AM EST - 3 months ago

Harmony Biosciences Provides Update on the Status of the Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia

Feb 18, 2025, 8:05 AM EST - 3 months ago

Harmony Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

Jan 24, 2025, 1:05 PM EST - 4 months ago

Harmony Biosciences: Don't Sleep On This Enterprising, Profitable Biotech

Jan 13, 2025, 8:05 AM EST - 5 months ago

Harmony Biosciences Reports Strong 2024 Revenues, Provides 2025 Revenue Guidance and Highlights Key Pipeline Catalysts

Dec 18, 2024, 8:05 AM EST - 6 months ago

HARMONY BIOSCIENCES TO PRESENT AT THE 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Dec 3, 2024, 8:05 AM EST - 6 months ago

Market Cap	2.02B
Revenue (ttm)	714.73M
Net Income (ttm)	145.49M
EPS (ttm)	N/A
PE Ratio	13.48
Forward PE	10.74
Profit Margin	20.36%
Debt to Equity Ratio	0.24

Volume	441,100
Avg Vol	700,500
Day's Range	N/A - N/A
Shares Out	57.42M
Stochastic %K	64%
Beta	0.87
Analysts	Strong Sell
Price Target	$51.44